The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas1
Open Access
- 1 January 2007
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 9 (1), 47-52
- https://doi.org/10.1215/15228517-2006-024
Abstract
Temozolomide (TMZ) administered daily with radiation therapy (RT) for six weeks, followed by adjuvant TMZ for six months, has become standard therapyKeywords
This publication has 21 references indexed in Scilit:
- A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastomaInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade gliomaJournal of Neuro-Oncology, 2005
- Phase II study of temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiformeInternational Journal of Radiation Oncology*Biology*Physics, 2004
- Selective CD4+ Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic ImplicationsJournal of Clinical Oncology, 2004
- Phase I study of mitozolomide on a once daily for 5 days scheduleCancer Chemotherapy and Pharmacology, 1990
- Phase Ii Trial of Mitozolomide in Patients with Advanced Ovarian Cancer: A Study of the Eortc Gynecological Cancer Cooperative GroupActa Oncologica, 1989
- Simplified Calculation of Body-Surface AreaNew England Journal of Medicine, 1987
- Polychemotherapie des metastasierenden MelanomsDeutsche Medizinische Wochenschrift (1946), 1976
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976